Your Key to European Markets

The key to refreshingly smart European Market Access

We develop focused and valuable Pricing and Market Access strategies that satisfy health technology evaluators and decision makers, and are equally beneficial for patients and physicians. These strategies enable you to successfully engage in the European Markets.

Discover More


The answer to the How?

Our consulting approach builds on your studies and evidence, and integrates the value drivers and market access experiences into one strategy.

Discover more

Market Access

The ‘perfect market access‘ or the ‘perfect storm’!

European market access challenges usually have acronyms: NICE, HAS, AMNOG, AIFA and CIMP – which give evidence of the global megatrend for rigorous assessments in reimbursement decisions of health technologies (Health Technology Assessment (HTA)).

Discover more


Value determination, demonstration and communication.

It is not simply a question of determining how much payers will pay for drugs. It is a question, of how much of the value can you demonstrate within the clinical trial results, and how much clinical and economic justification do you have to supplement from other evidence sources.

Discover more

How can we help you?

As our client and partner, 100 local experts are at your service.

Being members and/or coordinators of several EU teams, our team has extensive experience in supporting companies for market access, pricing and reimbursement activities. More than 200 successful submissions in many countries and across all therapeutic areas prove our wide experience and expertise.

Contact us

Our Network

About us

The Pharos network is a highly specialised consulting network of 7 renowned agencies with experience in delivering a winning launch across Europe at a fair price.


Learn how we develop focused and valuable Pricing and Market Access strategies for health technology evaluators and decision makers by following our regular news from our partner network.

Capturing the value of environmental impact and sustainability in pharmaceutical health technology assessment

HTA outcome for ATMPs in the three Scandinavian countries Sweden, Norway, Denmark

Valtermed: The Spanish National Health System’s information system that collects real world evidence on the therapeutic value of new therapeutics

New Horizonscan reveals upcoming pharmaceutical advances